Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
If you have been diagnosed with multiple myeloma you are going to experience short, long-term and late stage collateral damage aka side effects. Side effects are not the issue. The issue the MM patient must face is how to best manage the side effects he/she experiences. Consider integrative multiple myeloma therapies.
The article linked below explains that half of MMers who undergo carfilzomib (kyprolis) will experience heart damage within the the vast majority (86%) of patients experiencing their heart damage within the first three months of therapy.
At this point it is important for me to point out that it is more than likely that MMers experience heart damage that does not show up until long after active therapy has stopped. I developed chemotherapy-induced chronic atrial fibrillation about nine (9) years after my induction therapy and ASCT in 12/95.
My point is that the study linked below cites heart damage that occurs in the months immediately following chemotherapy. The MMer’s goal is to think long-term about his/her health. Integrative multiple myeloma therapy may prevent heart failure post MM chemotherapy.
Evidence-based but non-conventional therapies for reducing or eliminating heart damage run from
I am both a MM survivor and MM cancer coach. If you would like to learn more about integrative MM therapies to both increase the efficacy of conventional chemotherapy while reducing its toxicity, please scroll down the page, post a question or comment and I will reply to you ASAP.
“In patients receiving therapy for relapsed multiple myeloma, heart failure, angina, and other cardiovascular adverse events occurred more frequently with carfilzomib compared with bortezomib, according to a study…
The observational, multi-institutional study followed 97 patients starting proteasome inhibitor therapy for relapsed multiple myeloma over a median 14 months: 65 patients received a chemotherapy regimen that included carfilzomib, and 32 patients received a regimen that included bortezomib…
In all, 61 cardiovascular adverse events occurred. Among evaluable patients, 50% receiving carfilzomib and 15% receiving bortezomib experienced at least one cardiovascular adverse event. The median time from treatment start to cardiovascular adverse event was 33 days, and 86% of all such events occurred within the first 3 months of treatment…
“In the present study, we investigated the cardioprotective effects of coenzyme Q10 (Q10) against doxorubicin (DOXO) induced cardiomyopathy…
At the end of 14 days, systolic, diastolic and mean blood pressure, electrocardiogram (ECG), complete blood count, and serum biochemical profile were evaluated.
We also analyzed heart histological and ultrastructure analysis, and estimated heart’s oxidative stress and lipid peroxidation. DOXO administration altered ECG, with increase heart rate, P-wave duration, PR interval duration, and T-wave amplitude.
All the parameters were significantly reduced following Q10 treatment. DOXO also caused increase in CK, CK-MB, LDH, and urea levels, which were not mitigated by Q10 treatment.
However, Q10 reduced oxidative stress by interfering with superoxide dismutase, significantly decreasing lipid peroxidation in heart tissue.
DOXO administration also leads to several histological and ultrastructure alterations including cardiomyocyte degeneration and intense intracelullar autophagosomes, all minimized by Q10 treatment.
Q10 treatment prevented the ECG changes, minimized oxidative stress, lipid peroxidation, and DOXO-induced heart tissue alterations.
Our findings suggest that pre- and post-treatment with Q10 exerts potential cardioprotective effect against the DOX-induced cardiotoxicity.”